The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces caspase-dependent and -independent apoptosis in acute myelogenous leukemia

Cancer Research

Volumn 64, Issue 21, 2004, Pages 7927-7935

  Konopleva, Marina ^a   Tsao, Twee ^a   Estrov, Zeev ^a   Lee, Ruey Min ^b   Wang, Rui Yu ^a   Jackson, C Ellen ^a   McQueen, Teresa ^a   Monaco, Giuseppe ^c   Munsell, Mark ^a   Belmont, John ^c   Kantarjian, Hagop ^a   Sporn, Michael B ^d   Andreeff, Michael ^a,e  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d DARTMOUTH MEDICAL SCHOOL   (United States)

^e Dept Blood and Marrow Transplant ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CYANO 3,12 DIOXOOLEANA 1,9 DIEN 28 OIC ACID; ANTINEOPLASTIC AGENT; CASPASE; CASPASE 8; CASPASE 9; CYTOCHROME C; PROTEIN BCL 2; RNA; TRITERPENOID; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS INDUCING FACTOR; CASPASES; CELL DIVISION; CELL LINE; FLAVOPROTEINS; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MEMBRANE POTENTIALS; MEMBRANE PROTEINS; MITOCHONDRIA; OLEANOLIC ACID; PHOSPHATIDYLSERINES; PPAR GAMMA; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 7444241538     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-2402     Document Type: Article

References (54)

1. Baer MR, George SL, Dodge RK, et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 2002;100:1224-32.
2. Beran M, Estey E, O'Brien S. et al. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J Clin Oncol 1999;17:2819-30.
3. Schimmer AD, Hedley DW, Penn LZ, Minden MD. Receptor- and mitochondrial-mediated apoptosis in acute leukemia: a translational view. Blood 2001;98:3541-53.
4. Ibrado AM, Huang Y, Fang G, Liu L, Bhalla K. Overexpression of Bcl-2 or Bcl-xL inhibits Ara-C-induced CPP32/Yama protease activity and apoptosis of human acute myelogenous leukemia HL-60 cells. Cancer Res 1996;56:4743-8.
5. Sun SY, Hail N Jr, Lotan R. Apoptosis as a novel target for cancer chemoprevention. J Natl Cancer Inst (Bethesda) 2004;96:662-72.
6. Konopleva M, Zhao S, Xie Z, et al. Apoptosis: molecules and mechanisms. Adv Exp Med Biol 1998;457:217-36.
7. Kornblau S, Konopleva M, Andreeff M. Apoptosis regulating proteins as targets of therapy for hematological malignancies. Expert Opin Investig Drugs 1999;8:2027-57.
8. Tamm I, Kornblau SM, Segall H, et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 2000;6:1796-803.
9. Andreeff M, Jiang S, Zhang X, et al. Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid. Leukemia 1999;13:1881-92.
10. Schimmer AD, Pedersen IM, Kitada S, et al. Functional blocks in caspase activation pathways are common in leukemia and predict patient response to induction chemotherapy. Cancer Res 2003;63:1242-8.
11. Eksioglu-Demiralp E, Kitada S, Carson D, Garland J, Andreeff M, Reed JC. A method for functional evaluation of caspase activation pathways in intact lymphoid cells using electroporation-mediated protein delivery and flow cytometric analysis. J Immunol Methods 2003;275:41-56.
12. Andreeff M, Konopleva M. Mechanisms of drug resistance in AML. In: Murray D, Andersson BS, editors. Clinically relevant resistance in cancer chemotherapy. Norwell, MA: Kluwer Academic Publishers; 2002. p. 237-62.
13. Joza N, Susin SA, Daugas E, et al. Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. Nature (Lond) 2001;410:549-54.
14. Suzuki Y, Imai Y, Nakayama H, Takahashi K, Takio K, Takahashi R. A serine protease, htra2, is released from the mitochondria and interacts with xiap, inducing cell death. Mol Cell 2001;8:613-21.
15. Li LY, Luo X, Wang X. Endonuclease G is an apoptotic DNase when released from mitochondria. Nature (Lond) 2001;412:95-9.
16. Warrell RP Jr, Frankel SR, Miller WH Jr, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 1991;324:1385-93.
17. Suh N, Wang Y, Honda T, et al. A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity. Cancer Res 1999;59:336-41.
18. Konopleva M, Tsao T, Ruvolo P, et al. Novel synthetic triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia. Blood 2002;99:326-35.
19. Wang Y, Porter WW, Suh N, et al. A synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor gamma. Mol Endocrinol 2000;14:1550-6.
20. Kitamura S, Miyazaki Y, Shinomura Y, Kondo S, Kanayama S, Matsuzawa Y. Peroxisome proliferator-activated receptor gamma induces growth arrest and differentiation markers of human colon cancer cells. Jpn J Cancer Res 1999;90:75-80.
21. Mueller E, Sarraf P, Tontonoz P, et al. Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1998;1:465-70.
22. Palakurthi SS, Aktas H, Grubissich LM, Mortensen RM, Halperin JA. Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation. Cancer Res 2001;61:6213-8.
23. Ito Y, Pandey P, Place A, et al. The novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid induces apoptosis of human myeloid leukemia cells by a caspase-8-dependent mechanism. Cell Growth Differ 2000;11:261-7.
24. Stadheim TA, Suh N, Ganju N, Sporn MB, Eastman A. The novel triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) potently enhances apoptosis induced by tumor necrosis factor in human leukemia cells. J Biol Chem 2002;277:16448-55.
25. Ito Y, Pandey P, Sporn MB, Datta R, Kharbanda S, Kufe D. The novel triterpenoid CDDO induces apoptosis and differentiation of human osteosarcoma cells by a caspase-8 dependent mechanism. Mol Pharmacol 2001;59:1094-9.
26. Ikeda T, Sporn M, Honda T, Gribble GW, Kufe D. The novel triterpenoid CDDO and its derivatives induce apoptosis by disruption of intracellular redox balance. Cancer Res 2003;63:5551-8.
27. Hail N Jr, Konopleva M, Sporn M, Lotan R, Andreeff M. Evidence supporting a role for calcium in apoptosis induction by the synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO). J Biol Chem 2004;279:11179-87.
28. Honda T, Rounds BV, Gribble GW, Suh N, Wang Y, Sporn MB. Design and synthesis of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, a novel and highly active inhibitor of nitric oxide production in mouse macrophages. Bioorg Med Chem Lett 1998;8:2711-4.
29. Wang J-L, Liu D, Zhang Z-J, et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci USA 2000;97:7124-9.
30. Andreeff M, Leysath C, Konopleva M, Huang Z. Induction of apoptosis in AML by HA14-1, a cell-permeable organic compound identified by protein structure-based computer screening that binds the BH1 to BH3 surface pocket of Bcl-2. Blood 2000;96:502a.
31. Juo P, Kuo CJ, Yuan J, Blenis J. Essential requirement for caspase-8/FLICE in the initiation of the Fas-induced apoptotic cascade. Curr Biol 1998;8:1001-8.
32. Huang Y, Ibrado AM, Reed JC, et al. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells. Leukemia 1997;11:253-7.
33. Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F, Berger R. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 1991;77:1080-6.
34. Andersson BS, Bergerheim US, Collins VP, et al. KBM-3, an in vitro model of human acute myelomonocytic leukemia. Exp Hematol 1992;20:361-7.
35. Kuida K, Haydar TF, Kuan CY, et al. Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase 9. Cell 1998;94:325-37.
36. McManus MT, Sharp PA. Gene silencing in mammals by small interfering RNAs. Nat Rev Genet 2002;3:737-47.
37. Bidere N, Lorenzo HK, Carmona S, et al. Cathepsin D triggers Bax activation, resulting in selective apoptosis-inducing factor (AIF) relocation in T lymphocytes entering the early commitment phase to apoptosis. J Biol Chem 2003;278:31401-11.
38. Buick RN, Till JE, McCulloch EA. A colony assay for proliferative blast cells circulating in myeloblastic leukemia. Lancet 1977;1:862-3.
39. Estrov Z, Black RA, Sleath PR, et al. Effect of interleukin-1 beta converting enzyme inhibitor on acute myelogenous leukemia progenitor proliferation. Blood 1995;86:4594-602.
40. Drach J, McQueen T, Engel H, Andreeff M, Maise R, Braylan R. Retinoic acid-induced expression of CD38 antigen in myeloid cells is mediated through retinoic acid receptor-α. Cancer Res 1994;54:1746-52.
41. Clodi K, Kliche K-O, Zhao S, et al. Cell-surface exposure of phosphatidylserine correlates with the stage of fludarabine-induced apoptosis in chronic lymphocytic leukemia (CLL) and expression of apoptosis-regulating genes. Cytometry 2000;40:19-25.
42. Poot M, Pierce RH. Detection of changes in mitochondrial function during apoptosis by simultaneous staining with multiple fluorescent dyes and correlated multiparameter flow cytometry. Cytometry 1999;35:311-7.
43. Zapata JM, Takahashi R, Salvesen GS, Reed JC. Granzyme release and caspase activation in activated human T- lymphocytes. J Biol Chem 1998;273:6916-20.
44. Andreeff M, Darzynkiewicz Z, Sharpless TK, Clarkson BD, Melamed MR. Discrimination of human leukemia subtypes by flow cytometric analysis of cellular DNA and RNA. Blood 1980;55:282-93.
45. Liu J, Dai Q, Chen J, et al. Phospholipid scramblase 3 controls mitochondrial structure, function, and apoptotic response. Mol Cancer Res 2003;1:892-902.
46. Andersson BS, Bergerheim US, Collins VP, et al. KBM-3, an in vitro model of human acute myelomonocytic leukemia. Exp Hematol 1992;20:361-7.
47. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
48. Johansen M, Kempen E, Newman RA, Nguyen J, Madden T. Preclinical pharmacokinetics of oral and intravenous CDDO, a novel triterpenoid antitumor agent. Proc Am Assoc Cancer Res 2002;43:591.
49. Green DR, Reed JC. Mitochondria and apoptosis. Science (Wash D C) 1998;281:1309-12.
50. Carter BZ, Kornblau SM, Tsao T, et al. Caspase-independent cell death in AML: caspase inhibition in vitro with pan-caspase inhibitors or in vivo by XIAP or survivin does not affect cell survival or prognosis. Blood 2003;102:4179-86.
51. Susin SA, Lorenzo HK, Zamzami N, et al. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature (Lond) 1999;397:441-6.
52. Casasa F, Domenjoudb L, Rocharda P, et al. A 45 kDa protein related to PPAR-gamma2, induced by peroxisome proliferators, is located in the mitochondrial matrix. FEBS Lett 2000;478:8.
53. Nisoli E, Clementi E, Paolucci C, et al. Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide. Science (Wash D C) 2003;299:896-9.
54. Honda T, Rounds BV, Gribble GW, Suh N, Wang Y, Sporn MB. Design and synthesis of 2-cyano-3,12-dioxoolean-l,9-dien-28-oic acid, a novel and highly active inhibitor of nitric oxide production in mouse macrophages. Bioorg Med Chem Lett 1998;8:2711-4.